Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Piramal Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹161.72
High
₹165.34
Price Summary
| Previous Close | ₹163.35 |
|---|---|
| Day's Range | ₹161.72 - ₹165.34 |
| Open | ₹164.05 |
| 52 Week Range | ₹132.30 - ₹220.85 |
| Volume | 23,30,467 |
| Market Cap | ₹0.02 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 3,813.56 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -2.45 |
| P/E Ratio | 326.26 |
| Book Value(₹) | 2.66 |
| PAT Margin (%) | 0.86 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 6.61 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 52857.1 | 27540.7 |
| Expenses | N/A | N/A |
| PBT | 9111.4 | 2728.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 6914.0 | 1535.0 |
About Piramal Pharma Ltd.
| Founded | 2020 |
|---|---|
| NSE Symbol | PPLPHARMA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,36,666.97 | 1,819.95 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,76,804.73 | 6,660.10 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,50,554.07 | 4,447.00 | 3,140.10 - 3,140.10 |
| Apollo Hospitals Enterprise Ltd. | 1,21,241.38 | 8,454.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,09,119.71 | 1,348.10 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,06,811.74 | 1,064.00 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,05,919.50 | 1,269.00 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,645.47 | 2,266.80 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 99,869.41 | 1,026.15 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,611.60 | 2,361.95 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Piramal Pharma informs about updates
Piramal Pharma informs about updates
Piramal Pharma informs about updates
Piramal Pharma informs about ESG ratings
Piramal Pharma has informed that as per the information received by the Company on March 20, 2026, SES ESG Research (‘SES ESG’), has assigned an Environment, Social and Governance (‘ESG’) Rating of ‘68.5’ for the Company for FY 2024-25 based on data made available by the Company in public domain for that year. The link for the rating as published is also available on the website. The Company has not engaged SES ESG for ESG Rating. SES ESG has voluntarily prepared the report considering the ESG factors reported by the Company. This intimation is also being uploaded on the website of the Company at https://www.piramalpharma.com/.
The above information is a part of company’s filings submitted to BSE.
Fermenta Biotech informs about investor meeting
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Fermenta Biotech has informed that the Company, through its officials, will be participating in meeting(s) with investors on June 22, 2026 in Mumbai (One-to-one). The company has further informed that the Press Release dated May 26, 2026 regarding audited Financial results for the year ended March 31, 2026 and relevant Investor Presentation proposed to be discussed with investor(s) in the above interaction is uploaded on the website of the Company: www.fermentabiotech.com and on BSE’ website: www.bseindia.com. No unpublished price sensitive information (UPSI) is intended to be discussed during the interaction.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Piramal Pharma Ltd. is ₹163.35 as of 2026-06-17.
The market capitalisation of Piramal Pharma Ltd. is ₹21,754.23 as of 2026-06-17.
The 1-year return of Piramal Pharma Ltd. is 0.00% as of 2026-06-17.
The P/E ratio of Piramal Pharma Ltd. is 326.26 as of 2026-06-18.
The 52-week high and low of Piramal Pharma Ltd. are ₹220.85 and ₹132.30, respectively, as of 2026-06-17.
People Also Ask
Piramal Pharma Ltd. manufactures a range of complex hospital generics, including inhalation anesthetics and injectables. The company also offers a line of consumer healthcare products and provides comprehensive contract development and manufacturing services (CDMO) for global firms.
Piramal Pharma Ltd. establishes partnerships by offering extensive CDMO services, acting as an integrated manufacturing partner for global pharmaceutical innovators. The firm also partners directly with major healthcare institutions to supply hospital generics and complex anesthesia products.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
